The Role of CX3CL1 and ADAM17 in Pathogenesis of Diffuse Parenchymal Lung Diseases
| Autor: | Brian König, Martina Ganovska, Eva Tedlova, Frantisek Sandor, M Suchankova, Vladimir Leksa, Maria Bucova, Jan Urban |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Medicine (General) Clinical Biochemistry Population diffuse parenchymal lung diseases fibrotic process Article CX3CL1 Pathogenesis 03 medical and health sciences Idiopathic pulmonary fibrosis 0302 clinical medicine R5-920 medicine education education.field_of_study ADAM17 Lung bronchoalveolar lavage fluid medicine.diagnostic_test business.industry respiratory system medicine.disease 030104 developmental biology medicine.anatomical_structure Bronchoalveolar lavage 030228 respiratory system business Hypersensitivity pneumonitis CD8 |
| Zdroj: | Diagnostics, Vol 11, Iss 1074, p 1074 (2021) Diagnostics Volume 11 Issue 6 |
| ISSN: | 2075-4418 |
| Popis: | Fractalkine (CX3CL1) is a unique chemokine that functions as a chemoattractant for effector cytotoxic lymphocytes and macrophages expressing fractalkine receptor CX3CR1. CX3CL1 exists in two forms—a soluble and a membrane-bound form. The soluble CX3CL1 is released from cell membranes by proteolysis by the TNF-α-converting enzyme/disintegrin-like metalloproteinase 17 (TACE/ADAM17) and ADAM10. In this study, we evaluated the diagnostic relevance and potential roles of CX3CL1 and ADAM17 in the pathogenesis of diffuse parenchymal lung diseases (DPLDs) in the human population. The concentration of CX3CL1 and ADAM17 was measured by the enzyme-linked immunosorbent assay (ELISA) test in bronchoalveolar lavage fluids of patients suffering from different DPLDs. The concentration of CX3CL1 was significantly higher in patients suffering from idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis patients compared to the control group. A significantly higher concentration of CX3CL1 was measured in fibrotic DPLDs compared to non-fibrotic DLPD patients. We found a positive correlation of CX3CL1 levels with the number of CD8+ T cells, and a negative correlation with CD4+ T cells in BALF and diffusion capacity for carbon monoxide. The concentration of ADAM17 was significantly lower in the IPF group compared to the other DPLD groups. We noticed a significantly higher CX3CL1/ADAM17 ratio in the IPF group compared to the other DPLD groups. We suggest that CX3CL1 has a distinctive role in the pathogenesis of DPLDs. The level of CX3CL1 strongly correlates with the severity of lung parenchyma impairment. The results suggest that high values of CX3CL1/ADAM17 could be diagnostic markers for IPF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|